Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

Minerva Endocrinology 2026 Open access

Read full text
Authors: Giuseppe Seminara, Marco Leuzzi, Leonardo MEDURI, Emanuela A. GRECO, Antônio Aversa
DOI: 10.23736/s2724-6507.26.04541-0
Cited by: 4
References: 25

Abstract

BACKGROUND: Male obesity-associated hypogonadism promotes a vicious cycle of sarcopenic obesity and increased cardiometabolic risk. Although tirzepatide is highly effective for weight loss, a subset of "late responders" has been reported, and treatment-induced lean body mass (LBM) depletion remains a significant clinical concern. This pilot study evaluated the efficacy of adding testosterone undecanoate (TRT) to tirzepatide in this specific population. METHODS: ) with functional secondary hypogonadism after ≥3 months of treatment with tirzepatide and

Fields of Study & Subjects

Hormonal and reproductive studies Pharmacology and Obesity Treatment Regulation of Appetite and Obesity

Publication details

Journal / source
Minerva Endocrinology
Publisher
Edizioni Minerva Medica
Volume
51
Issue
2
Pages
104–117
Publication date
9 March 2026
Language
EN